Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
AssigneeLunella Biotech, Inc.
InventorsMichael P. LISANTI, Federica SOTGIA
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to inhibitors of mitochondrial function. Methods of treating hypoxic cancer cells using anti-angiogenic agents and mitochondrial biogenesis inhibitors are disclosed. Tetracyclines, such as doxycycline, may serve as mitochondrial biogenesis inhibitors. Also described are methods of sensitizing hypoxic cancer cells to one or more chemotherapies by administering a mitochondrial biogenesis inhibitor with the chemotherapy.
Claims18
A method of treating hypoxic cancer stem cells (CSCs) comprising administering a therapeutically effective amount of an anti-angiogenic agent and a therapeutically effective amount of a mitochondrial biogenesis inhibitor.
A method of sensitizing hypoxic cancer stem cells CSCs to a chemotherapy, the method comprising:
- administering a therapeutically effective amount of a mitochondrial biogenesis inhibitor with a chemotherapeutic agent.
A compound for treating hypoxic cancer stem cells (CSCs), the compound comprising:
- an anti-angiogenic agent and a therapeutically effective amount of a mitochondrial biogenesis inhibitor.
A compound for sensitizing hypoxic cancer stem cells (CSCs) to one or more chemotherapies, the compound comprising:
- a mitochondrial biogenesis inhibitor and a chemotherapeutic agent.
A method of sensitizing hypoxic cancer stem cells (CSCs) to radiotherapy, the method comprising:
- administering a therapeutically effective amount of a mitochondrial biogenesis inhibitor with radiotherapy.
Dependencies are inferred from the claim text.